AMENDMENTS TO THE CLAIMS

Please cancel claim 19.

Listing of Claims

1. **(Original)** 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole of structural formula I:



(I)

characterized as being a crystalline anhydrate.

2. **(Original)** The crystalline anhydrate of Claim 1 characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.19, 6.09, 4.57, 4.19, 4.06, and 3.20 angstroms.

3. **(Original)** The crystalline anhydrate of Claim 2 further characterized by the X-ray powder diffraction pattern of FIG. 1.

4. **(Original)** The crystalline anhydrate of Claim 1 characterized by the solid state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 2.

5. **(Original)** The crystalline anhydrate of Claim 1 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals with chemical shift values of 158.9, 158.2, 143.0, 129.3, 127.2, 43.5, 36.6, 26.4, and 7.6 p.p.m.

6. **(Original)** The crystalline anhydrate of Claim 5 characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 3.

7. **(Original)** The crystalline anhydrate of Claim 1 characterized by the differential scanning calorimetric (DSC) curve of FIG. 4.

8. **(Original)** The crystalline anhydrate of Claim 1 characterized by the thermogravimetric analyis (TGA) curve of FIG. 5.

9. **(Original)** 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole of structural formula I:



(I)

characterized as being a crystalline monohydrate.

10. **(Original)** The crystalline monohydrate of Claim 9 characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 8.08, 6.49, 5.43, 5.39, 4.38, 4.10, 3.18, and 2.74 angstroms.

11. **(Original)** The crystalline monohydrate of Claim 10 further characterized by the X-ray powder diffraction pattern of FIG. 6.

12. **(Original)** The crystalline monohydrate of Claim 9 characterized by the solid state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 7.

13. **(Original)** The crystalline monohydrate of Claim 9 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals with chemical shift values of 161.5, 157.8, 143.4, 132.3, 130.0, 128.5, 126.9, 125.9, 45.5, 37.2, 26.4, and 7.7 p.p.m.

14. **(Original)** The crystalline monohydrate of Claim 13 characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 8.

15. **(Original)** The crystalline monohydrate of Claim 9 characterized by the differential scanning calorimetric (DSC) curve of FIG. 9.

16. **(Original)** The crystalline monohydrate of Claim 9 characterized by the thermogravimetric analyis (TGA) curve of FIG. 10.

17. **(Original)** A pharmaceutical composition comprising a therapeutically effective amount of the crystalline anhydrate of Claim 1 or the crystalline monohydrate of Claim 9 in association with one or more pharmaceutically acceptable carriers or excipients.

18. **(Original)** A method of treating Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment comprising administering to a mammal in need of such treatment a therapeutically effective amount of the crystalline anhydrate of Claim 1 or the crystalline monohydrate of Claim 9.

19. **(Cancelled)** Use of the crystalline anhydrate of Claim 1 or the crystalline monohydrate of Claim 9 as active ingredient in the manufacture of a medicament for use in the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment in a mammal.

20. **(Original)** 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole of structural formula I:



(I)

characterized as being a crystalline toluene solvate.

21. **(Original)** The crystalline toluene solvate of Claim 20 characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.13, 6.74, 5.95, 4.38, 3.83, 3.61, 3.42, 3.14, and 2.30 angstroms.

22. **(Original)** The crystalline toluene solvate of Claim 21 further characterized by the X-ray powder diffraction pattern of FIG. 11.

23. **(Original)** The crystalline toluene solvate of Claim 20 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals with chemical shift values of 165.2, 158.8, 143.5, 136.0, 128.8, 128.0, 127.4, 120.0, 119.0, 117.6, 36.6, 26.8, 21.0, and 7.8 p.p.m.

24. **(Original)** The crystalline toluene solvate of Claim 23 characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 12.

25. **(Original)** The crystalline toluene solvate of Claim 20 characterized by the differential scanning calorimetric (DSC) curve of FIG. 13.

26. **(Original)** The crystalline toluene solvate of Claim 20 characterized by the thermogravimetric analysis (TGA) curve of FIG. 14.